Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial

IMPORTANCE: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized clinical trial was stopped early owing to the efficacy of low-dose rivaroxaban plus aspirin in preventing major cardiovascular events. The main reason for early trial termination was the effect o...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Neurol
Main Authors: Perera, Kanjana S., Ng, Kelvin K. H., Nayar, Sumiti, Catanese, Luciana, Dyal, Leanne, Sharma, Mukul, Connolly, Stuart J., Yusuf, Salim, Bosch, Jackie, Eikelboom, John W., Hart, Robert G.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2019
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6749537/
https://ncbi.nlm.nih.gov/pubmed/31524941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.2984
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים